Association of Clinical Markers With Disease Progression in Patients With Vitiligo From China.
暂无分享,去创建一个
Qianqian Wang | Chengfeng Zhang | Xiuxiu Wang | Shujun Chen | L. Xiang | Ziqi Liu | M. Jiang | Li Zhang | Yuli Kang | Fang Yan
[1] R. L. Riding,et al. The Role of Memory CD8+ T Cells in Vitiligo , 2019, The Journal of Immunology.
[2] J. Tso,et al. Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo , 2018, Science Translational Medicine.
[3] A. Pandya,et al. The majority of patients presenting with vitiligo have a clinical sign of activity , 2017, Journal of the American Academy of Dermatology.
[4] S. de Schepper,et al. Biomarkers of disease activity in vitiligo: A systematic review. , 2017, Autoimmunity reviews.
[5] John E. Harris,et al. Vitiligo: Mechanistic insights lead to novel treatments , 2017, The Journal of allergy and clinical immunology.
[6] K. Ezzedine,et al. New discoveries in the pathogenesis and classification of vitiligo. , 2017, Journal of the American Academy of Dermatology.
[7] J. Richmond,et al. Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity , 2017, Journal of the American Academy of Dermatology.
[8] A. Pandya,et al. Presentations, Signs of Activity, and Differential Diagnosis of Vitiligo. , 2017, Dermatologic clinics.
[9] T. Passeron,et al. Differential expression of CXCL9, CXCL10, and IFN‐γ in vitiligo and alopecia areata patients , 2017, Pigment cell & melanoma research.
[10] Jia-qiang Wu,et al. Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo , 2016, The British journal of dermatology.
[11] K. Ezzedine,et al. Vitiligo , 2015, The Lancet.
[12] P. Bahadoran,et al. Maintenance therapy of adult vitiligo with 0.1% tacrolimus ointment: a randomized, double blind, placebo-controlled study. , 2015, The Journal of investigative dermatology.
[13] C. Terwee,et al. Vitiligo Area Scoring Index and Vitiligo European Task Force assessment: reliable and responsive instruments to measure the degree of depigmentation in vitiligo , 2015, The British journal of dermatology.
[14] C. Hunter,et al. CXCL10 Is Critical for the Progression and Maintenance of Depigmentation in a Mouse Model of Vitiligo , 2014, Science Translational Medicine.
[15] E. Wherry,et al. A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8+ T cell accumulation in the skin , 2011, The Journal of investigative dermatology.
[16] A. Stratigos,et al. Efficacy, predictors of response, and long-term follow-up in patients with vitiligo treated with narrowband UVB phototherapy. , 2007, Journal of the American Academy of Dermatology.
[17] L. Montes,et al. Vitiligo , 2002, The Lancet.
[18] J. Yoo,et al. Clinical and histopathologic characteristics of trichrome vitiligo. , 2000, Journal of the American Academy of Dermatology.